Identifying markers of apathy in elderly patients with bipolar disorder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify reliable neurobehavioral markers of apathy in elderly individuals aged 70 to 85 with bipolar disorder. By measuring motor activity through actimetry, analyzing speech patterns using artificial intelligence, and conducting MRI scans, researchers will compare participants with bipolar disorder to healthy volunteers. The goal is to pinpoint individuals at high risk of cognitive decline and dementia. Participants will undergo cognitive testing to assess their verbal memory and fluency.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Population: Age between 70 and 85 years-old, living at home (Participants living in nursing homes are not included).
2. Condition: OABD type 1, type 2 and type 3 assessed by the DSM5 criteria
3. Stable: no MDE or hypomanic state within the last 6 months
4. Ambulatory setting only
5. General condition: Successful Gait speed test from the Short Physical Performance Battery (SPPB): beingable to walk 4 meters in 4 seconds (SPPB NIH Toolbox)44
6. Person affiliated to a social security regime
7. Patients who have given their free, informed and written consent to take part in the study

Exclusion Criteria:

1. Psychiatric conditions and or co-morbidities

   1. Unipolar depression
   2. Recurrent unipolar depression
   3. Substance use disorder according to DSM5 criteria. Benzodiaepine and/or z-drugs dependence are accepted.
2. Neurological and cerebral co-morbidities

   1. Major Cognitive Disorder: significant cognitive decline characterized by extensive cognitive tests or at least a standardized clinical evaluation AND at least loss of autonomy in complex instrumental daily living function, not related to delirium (DSM5 criteria)
   2. Medical history of known degenerative disorders: Alzheimer's disease, Lobar Degenerative Fronto-temporal disorders, Lewy Body disease, corticobasal degenerative disorder, Supranuclear Palsy, epilepsy.
   3. Medical history of known Parkinson's disease (according to the Movement Disorder Society (MDS)45 criteria)
   4. Medical history of known stroke
   5. Severe Parkinsonism (defined by MDS-Unified Parkinson's Disease Rating Scale46 \> 20)
3. MRI contra-indications: metallic implants, severe claustrophobia
4. Adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of their liberty.
5. Hospitalized at inclusion

Where it's running

• Centre Hospitalier Guillaume Regnier
  Rennes, Ile Et Vilaine, France Recruiting

Study contacts

• Principal investigator: Gabriel RG ROBERT — HC Guillaume Regnier
• Study coordinator: Gabriel RG ROBERT
• Email: g.robert@ch-guillaumeregnier.fr
• Phone: 0299333937

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effects of comorbidity on people with severe mental illness

  This study tests how having both alcohol/substance use and a severe mental illness affects hospitalizations, medications, and social participation among adults followed at a mental health center.

  Recruiting Abant Izzet Baysal University · Bolu, Bolu · NCT07692984

• Venous Tourniquet with Low-Dose Sugammadex vs Arterial Tourniquet for Seizure Monitoring During ECT

  40 patients undergoing ECT will have a venous tourniquet on one arm and an arterial tourniquet on the other to see which method better reveals motor seizures.

  Recruiting Medipol University · Istanbul · NCT07534475

• 7T MRI and visual perception markers for severe mood and psychotic disorders

  This project tests whether 7‑tesla MRI scans combined with visual perception tests can identify brain markers linked to diagnosis and treatment outcomes in adults with major depressive disorder, bipolar disorder, or schizophrenia.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07479758

• IRL757 for treating apathy in Parkinson's disease.

  This study will test whether the medication IRL757 is safe, easy to tolerate, and helps reduce apathy in people aged 50–90 with Parkinson's disease.

  Recruiting at 12 sites Phase 1/2 Integrative Research Laboratories AB · Pleven and 13 other locations · NCT07461220

• Emotional Eating, Sleep Quality, Mental State, and Metabolic Syndrome in Psychiatric Patients

  This study tests how mood, sleep, and emotional eating relate to metabolic syndrome in people with schizophrenia or bipolar disorder.

  Recruiting Abant Izzet Baysal University · Bolu, Bolu · NCT07411222

• Robotic technologies to reduce apathy in dementia

  This project will test whether two different home-based robotic programs can help people with mild cognitive impairment or dementia who have apathy become more motivated and engaged compared with standard occupational therapy.

  Recruiting at 2 sites University of Modena and Reggio Emilia · Milan, Italy and 1 other locations · NCT07404410

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.